SEC Comment Letter 0000000000-26-001921 to enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc.
Date: Feb. 25, 2026 · CIK: 0001980845 · Accession: 0000000000-26-001921
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293597
Letter
Re: enGene Holdings Inc. Registration Statement on Form S-3 Filed February 19, 2026 File No. 333-293597 Dear Lee Giguere:
February 25, 2026
Lee Giguere General Counsel enGene Holdings Inc. 4868 Rue Levy, Suite 220 Saint-Laurent, QC H4R 2P1
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Julio Vega
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> February 25, 2026 Lee Giguere General Counsel enGene Holdings Inc. 4868 Rue Levy, Suite 220 Saint-Laurent, QC H4R 2P1 Re: enGene Holdings Inc. Registration Statement on Form S-3 Filed February 19, 2026 File No. 333-293597 Dear Lee Giguere: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Julio Vega </TEXT> </DOCUMENT>